Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir

Mostrar otras versiones (1)

[Image: see text] The SARS-CoV-2 main protease (M(pro)) is the drug target of Pfizer’s oral drug nirmatrelvir. The emergence of SARS-CoV-2 variants with mutations in M(pro) raised the alarm of potential drug resistance. To identify potential clinically relevant drug-resistant mutants, we systematica...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yanmei, Lewandowski, Eric M., Tan, Haozhou, Zhang, Xiaoming, Morgan, Ryan T., Zhang, Xiujun, Jacobs, Lian M. C., Butler, Shane G., Gongora, Maura V., Choy, John, Deng, Xufang, Chen, Yu, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451032/
https://www.ncbi.nlm.nih.gov/pubmed/37637734
http://dx.doi.org/10.1021/acscentsci.3c00538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451032/
https://www.ncbi.nlm.nih.gov/pubmed/37637734
http://dx.doi.org/10.1021/acscentsci.3c00538

Ejemplares similares